Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
38.68 SEK | +5.97% | +9.55% | +47.10% |
04-18 | Transcript : Hansa Biopharma AB, Q1 2024 Earnings Call, Apr 18, 2024 | |
04-18 | Hansa Biopharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+47.10% | 215M | |
+38.99% | 50.93B | |
-0.14% | 42.12B | |
+49.62% | 42.05B | |
-7.20% | 29.18B | |
+13.00% | 26.02B | |
-22.44% | 18.9B | |
+8.60% | 13.21B | |
+24.56% | 12.17B | |
+29.91% | 12.16B |
- Stock Market
- Equities
- HNSA Stock
- News Hansa Biopharma AB
- Hansa Biopharma Receives Provisional Approval in Australia for Desensitization Treatment